secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001193125-23-065373
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine reports FY 2022 net loss of $121.8M; nominates first development candidate PM359 for CGD
--------------------------------------------------------------------------------

- Q4 2022 net loss $39.3M; full-year net loss $121.8M vs $165.4M in 2021.
- Cash, short-term investments $293.9M as of Dec 31, 2022, sufficient into 2025.
- Nominated PM359 as first development candidate for chronic granulomatous disease; IND-enabling studies planned in 2023.
- Preclinical proof-of-concept data for Friedreich's ataxia, cystic fibrosis, Wilson's disease, and PASSIGE technology disclosed.
- October 2022 IPO raised $180.2M net proceeds from upsized offering at $17.00 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000119312523065373/0001193125-23-065373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000119312523065373/d367061d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-065373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer